Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 23;1(2):pgac067. doi: 10.1093/pnasnexus/pgac067

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the National Academy of Sciences.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 2. — Sensitivity to type I IFN dose escalation. (A) Calu-3 cells were treated with increasing amounts of IFN-alpha prior to infection at an MOI of 0.01 for 24 h. Upper panel: titers and lower panel: data normalized to the nontreated control. Titer values below the detection level (dashed line) were set to 100 PFU/ml. (B) Regression analysis of the dose–response data shown in (A). Numbers underneath the virus names are estimators for the titers at 50 U/ml IFN, confidence intervals are given in brackets. All comparisons had P-values < 0.05. (C) Analysis of IFN dose–response curves in cells that were additionally pretreated with 1 µM Camostat. Note that for reasons of compatibility, pretreatment in (A) contained DMSO.